Telix Pharmaceuticals acquires ITM Isotope Technologies for $1.65B to secure radioisotope supply chain. Strategic pharma ...
European Commission approves icotrokinra (Icotyde) for moderate-to-severe plaque psoriasis in adults and adolescents. Learn about this IL-23 ...
European Commission approves obicetrapib monotherapy and ezetimibe combination for hypercholesterolemia treatment. Learn about Ubeslo and Evlarco approval.
Halozyme prices a $1.3 billion convertible notes offering to extend ENHANZE's IP runway and fund acquisitions. Read the latest details.
Greece's Anacalypsis Therapeutics secures pre-seed funding for AT001, a novel LRRK2-targeting stapled peptide for Parkinson's disease treatment. Learn more.
AbbVie collaborates with Iambic Therapeutics to accelerate AI-driven drug discovery across immunology, neuroscience, and oncology. Learn about the partnership.
Xenetic will acquire Santersus in an all-stock deal, uniting four NET-targeting clinical programs. Explore the biotech deal and its potential market impact.
Hanx Biopharmaceuticals secures access to XtalPi's AI-driven drug discovery platform for biologics development. Strategic partnership accelerates innovation.
Alkermes' orexin agonist ALKS 7290 demonstrates dose-dependent ADHD symptom reductions in proof-of-concept study. Learn about the breakthrough findings.
Xenon Pharmaceuticals submits azetukalner NDA to FDA for focal seizure treatment. KV7 potassium channel opener advances as psychiatry trials pause. Read more.
Vironexis' VNX-101 AAV gene therapy produces MRD-negative responses in relapsed/refractory ALL patients. Single-dose treatment shows durable results. Read more.
Aquestive resubmits Anaphylm NDA to FDA with redesigned packaging addressing safety concerns. Dibutepinephrine sublingual film for anaphylaxis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results